Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

Phase 1

Completed

Conditions: Neuroectodermal Tumor
Brain Metastases
Advanced Cancer

Interventions: Drug: Valproate
Drug: Etoposide

First Posted Date: 2007-08-08

Last Posted Date: 2012-09-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT00513162

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: AMD3100
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2007-08-07

Last Posted Date: 2016-12-12

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 52

Registration Number: NCT00512252

Locations: 🇺🇸
Washington University, St. Louis, Missouri, United States

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: Campath-1H
Drug: G-CSF
Drug: GM-CSF
Drug: BCNU
Drug: Stem Cell Transplant
Drug: Preparative Regimen for Allogenic Stem Cell Transplantation
Drug: Cytarabine
Drug: Etoposide
Drug: Melphalan
Drug: Campath
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: Low dose total body irradiation

First Posted Date: 2007-07-25

Last Posted Date: 2011-11-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT00505921

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Recombinant Interferon Alpha and Etoposide in Relapsed Osteosarcoma

Phase 2

Completed

Conditions: Osteosarcoma

Interventions: Drug: Etoposide
Drug: Interferon Alpha

First Posted Date: 2007-07-19

Last Posted Date: 2012-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00504140

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Treatment of Tumors of the Choroid Plexus Epithelium

Phase 3

Terminated

Conditions: Choroid Plexus Tumors

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Vincristine
Radiation: Radiation Therapy

First Posted Date: 2007-07-13

Last Posted Date: 2020-02-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00500890

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: topotecan hydrochloride
Procedure: Surgery
Drug: Isotretinoin
Drug: Filgrastim

First Posted Date: 2007-07-11

Last Posted Date: 2021-07-06

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 464

Registration Number: NCT00499616

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 186 locations

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Etoposide
Drug: G-CSF
Drug: GM-CSF
Drug: Isophosphamide
Drug: Rituximab
Procedure: Apheresis

First Posted Date: 2007-07-11

Last Posted Date: 2013-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00499343

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Phase 3

Conditions: Diffuse Large B-Cell Lymphoma
IPI≥2

Interventions: Drug: Rituximab
Drug: Vincristina
Drug: Ciclofosfamide
Drug: Prednisone
Drug: Doxorubicina
Drug: Pegfilgrastim
Drug: Mitoxantrone
Drug: ARA-C
Drug: Lenograstim
Drug: BCNU
Drug: VP-16
Procedure: ASCT

First Posted Date: 2007-07-11

Last Posted Date: 2011-02-15

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 399

Registration Number: NCT00499018

Locations: 🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹
Ospedale Umberto I - DH Oncoematologico, Nocera Inferiore, Salerno, Italy
🇮🇹
Az. Osp. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy

and more 71 locations

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2

Terminated

Conditions: Lymphoma, B-cell
Lymphoma, Non-Hodgkin
Diffuse Large B-cell Lymphoma (DLBCL)
Malignant Lymphoma, Non-Hodgkin

Interventions: Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Procedure: Total lymphoid irradiation (TLI)
Drug: Rituximab
Drug: Carmustine
Drug: Etoposide
Drug: Filgrastim
Drug: Anti-thymocyte globulin (ATG)
Drug: Cyclosporine
Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Hydrocortisone
Drug: Methylprednisolone

First Posted Date: 2007-06-04

Last Posted Date: 2018-05-14

Lead Sponsor: Stanford University

Target Recruit Count: 3

Registration Number: NCT00482053

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Cyclophosphamide
Drug: BCNU
Drug: Etoposide
Drug: Filgrastim
Drug: Antithymocyte globulin
Drug: Cyclosporine
Drug: Mycophenolate mofetil
Drug: Rituximab
Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Procedure: Total lymphoid irradiation
Drug: CD34+ Cells
Drug: Solu-Medrol

First Posted Date: 2007-06-04

Last Posted Date: 2018-02-14

Lead Sponsor: Stanford University

Target Recruit Count: 50

Registration Number: NCT00481832

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy